Evidence map›Paper›PMID 35216166›Full record

ArticleInternational journal of molecular sciences2022

Prodynorphin and Proenkephalin in Cerebrospinal Fluid of Sporadic Creutzfeldt-Jakob Disease.

Samir Abu-Rumeileh, Peggy Barschke, Patrick Oeckl, Simone Baiardi, Angela Mammana, Andrea Mastrangelo, Mhd Rami Al Shweiki, Petra Steinacker, Anna Ladogana, Sabina Capellari and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Samir Abu-RumeilehDepartment of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.ORCID 0000-0003-0631-8506
Peggy BarschkeDepartment of Neurology, Ulm University Hospital, 89081 Ulm, Germany.
Patrick OecklDepartment of Neurology, Ulm University Hospital, 89081 Ulm, Germany.ORCID 0000-0002-7652-7023
Simone BaiardiIRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Angela MammanaIRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Andrea MastrangeloIRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Mhd Rami Al ShweikiDepartment of Neurology, Ulm University Hospital, 89081 Ulm, Germany.
Petra SteinackerDepartment of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Anna LadoganaDepartment of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-7504-6906
Sabina CapellariIRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.
Markus OttoDepartment of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Piero ParchiIRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.ORCID 0000-0002-9444-9524
Istituto delle Scienze Neurologiche di Bologna · ITMartin Luther University Halle-Wittenberg · DEUniversity Hospital Ulm · DEGerman Center for Neurodegenerative Diseases · DEIstituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proenkephalin (PENK) and prodynorphin (PDYN) are endogenous opioid peptides mainly produced in the striatum and, to a lesser extent, in the cerebral cortex. Dysregulated metabolism and altered cerebrospinal fluid (CSF) levels of PENK and PDYN have been described in several neurodegenerative diseases. However, no study to date investigated these peptides in the CSF of sporadic Creutzfeldt-Jakob disease (sCJD). Using liquid chromatography-multiple reaction monitoring mass spectrometry, we evaluated the CSF PDYN- and PENK-derived peptide levels in 25 controls and 63 patients with sCJD belonging to the most prevalent molecular subtypes (MM(V)1, VV2 and MV2K). One of the PENK-derived peptides was significantly decreased in each sCJD subtype compared to the controls without a difference among subtypes. Conversely, PDYN-derived peptides were selectively decreased in the CSF of sCJD MV2K, a subtype with a more widespread overall pathology compared to the sCJD MM(V)1 and the VV2 subtypes, which we confirmed by semiquantitative analysis of cortical and striatal neuronal loss and astrocytosis. In sCJD CSF PENK and PDYN were associated with CSF biomarkers of neurodegeneration but not with clinical variables and showed a poor diagnostic performance. CSF PDYN and PENK-derived peptides had no significant diagnostic and prognostic values in sCJD; however, the distinct marker levels between molecular subtypes might help to better understand the basis of phenotypic heterogeneity determined by divergent neuronal targeting.

Indexed as

AgedAged, 80 and overBiomarkersCreutzfeldt-Jakob SyndromeEnkephalinsFemaleHumansMaleMiddle AgedNeuronsProtein PrecursorsBiomarkersEnkephalinspreproenkephalinproenkephalinProtein PrecursorsbiomarkersCreutzfeldt–Jakob diseasemass spectrometryopioid peptidesprion diseaseprodynorphinproenkephalin

Identifiers

PMID35216166
PMCPMC8877714
OpenAlexW4212784999

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.